Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients
Our study indicates that PARPi may increase the risk of MDS or AML after first-line maintenance treatment. No significant differences were found across the types of PARPi used.
Authors
- Nicola Gentili (ORCID: https://orcid.org/0000-0002-0066-9172)
- Gema Hernández (ORCID: https://orcid.org/0000-0003-4832-455X)
- Alberto Farolfi (ORCID: https://orcid.org/0000-0002-3289-8041)
- Daniela Montanari (ORCID: https://orcid.org/0009-0004-0010-0738)
- Giorgia Gurioli (ORCID: https://orcid.org/0000-0003-4036-5568)
- Ugo De Giorgi (ORCID: https://orcid.org/0000-0001-7520-2908)
- Sara Testoni (ORCID: https://orcid.org/0000-0001-6141-8783)
- Nicole Brighi (ORCID: https://orcid.org/0000-0002-1187-5481)
- Emilio Francesco Giunta (ORCID: https://orcid.org/0000-0002-5383-4469)
- Francesca Rusconi (ORCID: https://orcid.org/0000-0002-8995-6935)
- Chiara Casadei (ORCID: https://orcid.org/0000-0003-2467-749X)
Institutions
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- TriNetX (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf243
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05